Advanced Gastric Cancer Clinical Trial
Official title:
Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients: a Phase II Randomized Parallel Controlled Trial
Gastric cancer is one of the most common malignant tumors worldwide. With the rapid aging of global population, the number of elderly patients with local advanced gastric cancer is increasing. Surgery is the essential treatment for local advanced gastric cancer. However, because of the degeneration of physiological organs, cell functions, compensatory ability, immunity, and physiological reserve ability, elderly patients often face great safety issues when having surgery. Therefore, how to treat the elderly patients with local advanced gastric cancer with safe and effective surgery is one of the important problems in the field of gastric cancer treatment. With the introduction of minimally invasive treatment concepts and techniques, the role of laparoscopic radical gastrectomy in the treatment of early gastric cancer, as well as the advantages of trauma control and postoperative accelerated rehabilitation have been confirmed, however, there is still a lack of sufficient high-level clinical evidence in the elderly patients with advanced gastric cancer. The current study therefore aims to evaluate the safety and efficacy of laparoscopic versus open gastrectomy for advanced gastric cancer in elderly patients, using a randomized parallel controlled study design. The investigators hypothesized that laparoscopic gastrectomy is superior to open gastrectomy in terms of perioperative safety for local advanced gastric cancer patients aged 70 and above.
Gastric cancer is one of the most common cancer and cause of cancer death worldwide. With the
rapid aging of global population, the number of elderly patients with local advanced gastric
cancer has been continuously increasing. Surgery is the essential treatment for local
advanced gastric cancer. However, elderly patients are at high risk of postoperative
complications due to reduced functional reserve and increased comorbidities. Studies have
shown that elder patients can have postoperative complication incidence up to 18%-32% and
surgery-related mortality rate to 3.8%-9.5%. Therefore, elderly patients usually require more
restrict operative injury control compared to the younger population. Surgical safety and
effectiveness has become a crucial research focus for local advanced gastric cancer among
elderly patients.
Laparoscopic gastrectomy is one of the standard treatments for early gastric cancer and has
demonstrated its application value in local advanced gastric cancer. Two recent meta-analysis
on observational studies have shown the feasibility of laparoscopic gastrectomy in elderly
gastric cancer patients. Compared to conventional open resections, elderly patients may
benefit from the advantages of laparoscopic approach such as less trauma, less blood loss,
faster bowel movement recovery, earlier food intake, and shorter hospitalization. However,
laparoscopic gastrectomy raises issues such as prolonged operation time and disturbance of
circulatory and respiratory dynamics by carbon dioxide pneumoperitoneum during the procedure.
Nonetheless, all currently available evidence comes from observational studies that are
susceptible to bias and evidence on long-term survival is scarce. The investigators therefore
proposed to conduct this randomized controlled trial comparing the feasibility and survival
benefit of laparoscopic with open gastrectomy for elderly patients with local advanced
gastric cancer. The investigators hypothesized that laparoscopic gastrectomy is superior to
open gastrectomy in terms of perioperative safety for local advanced gastric cancer patients
aged 70 and above.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Completed |
NCT00821990 -
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01248403 -
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
|
Phase 3 | |
Not yet recruiting |
NCT01206218 -
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01851941 -
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
|
Phase 2 | |
Completed |
NCT00976768 -
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
|
Phase 2 | |
Active, not recruiting |
NCT03223376 -
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
|
Phase 3 | |
Completed |
NCT03609359 -
Lenvatinib and Pembrolizumab Simultaneous Combination Study
|
Phase 2 | |
Completed |
NCT03350477 -
Bioinformation Therapy for Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02935634 -
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03579784 -
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
|
Phase 2 | |
Completed |
NCT02952729 -
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
|
Phase 1 | |
Recruiting |
NCT02072317 -
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
|
Phase 2 | |
Terminated |
NCT01402401 -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
|
Phase 2 | |
Completed |
NCT01503372 -
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT01472250 -
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|
N/A | |
Recruiting |
NCT01015339 -
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 3 | |
Completed |
NCT00842491 -
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT02071043 -
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
|
Phase 2 |